China's First PMTA Non-Clinical Lab by Feelm Analysis Center

Jul.29.2022
China's First PMTA Non-Clinical Lab by Feelm Analysis Center
China's first non-clinical PMTA testing laboratory has been built by the Analytical Testing and Safety Assessment Center (ATSA).

Recently, it has been reported that the Analytical Testing and Safety Assessment Center (referred to as the "Safety Assessment Center") of Smoler has established China's first PMTA (pre-market tobacco application) comprehensive non-clinical testing laboratory. The laboratory currently covers PMTA non-clinical research requirements, including material safety, harmful and potentially harmful constituents (HPHCs) and toxicity testing.


This is the first PMTA testing laboratory established domestically, which will assist the global leading provider of closed-system electronic cigarette solutions, Smoore, and its flagship brand FEELM, in further improving product safety and helping partner brands successfully pass PMTA certification.


The only laboratory in China that covers all substances in HPHCs.


Before this, electronic cigarette companies that wanted to enter the international market had to rely on third-party partners to complete PMTA testing, which was expensive and time-consuming. With the establishment of a new domestic laboratory, FEELM's brand partners can more easily undergo PMTA certification, increasing their chances of entering the international market.


Dr. Long, the director of the Smyrna Evaluation Center, has revealed that the FDA has placed significant emphasis on HPHCs and has identified a list of 33 substances to be tested. The Smyrna Evaluation Center is currently capable of testing 37 substances and is the only laboratory in the country that has the ability to test all substances included in the list of HPHCs.


The laboratory conducted tests using the world-leading HPHCs (harmful and potentially harmful constituents) database developed by Philip Morris International, which is based on multiple authoritative international toxicity databases. In addition, the lab incorporated advanced computational toxicology software to predict unidentified and potential harmful constituents not included in the database, further enhancing Philip Morris's safety assessment capabilities.


Assist brand clients in entering the overseas market.


Since the establishment of its first basic research institute in 2017, Simoer has been continuously expanding its global leading detection projects and building a comprehensive product safety verification system. Currently, Simoer's safety evaluation center has established the industry's first E&L (extractables and leachables) analysis testing laboratory, raising the material safety standard for electronic atomization to medical grade, and recently completed a toxicity testing laboratory that is now open to FEELM customers.


Smol intends to become the driving force behind electronic cigarette brands approaching the FDA and other regulatory agencies, allowing the brand to enter a broader overseas market. To date, eight of their products have been approved by the FDA for market release, with several produced by Smol, indicating FDA recognition of the processes and testing mechanisms in their new laboratory in China. Concurrently, Smol is collaborating with brand partners and FEELM customers to expand their testing scope and provide stronger support for product design, while also preparing to release safety reports.


This article contains excerpts or reprints from third-party sources, and their copyright belongs to the original media and authors. If there is any infringement, please contact us for deletion. Any organization or individual who wants to reprint must contact the author and should not directly reprint.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
The U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives said on September 23 that it has joined the interagency Trade Fraud Task Force to strengthen enforcement against illegal, misdeclared and smuggled vape and tobacco products. ATF will bring its authority under the Prevent All Cigarette Trafficking Act into the task force, including registration, reporting, shipping and record-inspection requirements covering interstate sales of electronic nicotine delivery systems. ATF said the move will strengthen its ability to trace illicit products from U.S. points of entry through domestic trafficking and distribution networks.
News
Sep.28 by 2Firsts Perspectives
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06